Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
Conditions
Interventions
Telitacicept
Placebo
Locations
23
China
The First Affiliated Hospital of Anhui Medical College
Hefei, Anhui, China
The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
Hefei, Anhui, China
Beijing Hospital
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Start Date
December 2, 2023
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2025
Last Updated
May 6, 2025
NCT07104565
NCT06533098
NCT04402086
NCT07362238
NCT07362199
NCT07294365
Lead Sponsor
Beijing Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions